Skip to content

Niagen Bioscience, Inc.

NAGE· NasdaqCore metricsCIK 1386570

Medicinal chemicals & botanical products40 peers

Last sale
Nov 12, 2026 · +2.39%
Market cap
$169.48M
79.2M shares
Filings
981
$27.19M
Q3 2026+29.9% FY25 yoy
-$1.17M
Q3 2026+103.3% FY25 yoy
-$1.59M
Q3 2026+110.7% FY25 yoy
-$10.77M
Q3 2020derivedN/M FY19 yoy
-$0.01
Q3 2026+81.8% FY25 yoy
$69.51M
Q3 2026+45.6% FY25 yoy
$169.48M
16.6×
1.4×
2.0×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$2.1470.11%$5.02past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$129.42MFY 2025
$129.42M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$129,423,000reported
FY 20242024-12-31$99,597,000reported
FY 20232023-12-31$83,570,000reported
FY 20222022-12-31$72,050,000reported
FY 20212021-12-31$67,449,000reported
FY 20202020-12-31$59,257,000reported
FY 20192019-12-31$46,291,000reported
FY 20182018-12-31$31,557,000reported
FY 20172017-12-30$21,201,000reported
FY 20162016-12-31$21,664,648 revisedreported
FY 20152016-01-02$17,884,886 revisedreported
FY 20142015-01-03$15,313,179reported

Capital returns

Dividends and buybacks · FY2012 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$251.00K$251.00K—80.08M sh+3.0%—
FY2024—$0.00$0.00—77.75M sh+3.2%—
FY2018—$404.00K$404.00K—55.29M sh+0.8%—
FY2017—$0.00$0.00—54.84M sh+44.7%—
FY2012—$8.20K$8.20K—96.51M sh+6.1%—

Segments

Segments
Revenue by Segments, FY2019 to FY2025FY2019Consumer Products segment · FY2019 · $36.08MIngredients segment · FY2019 · $6.20MAnalytical Reference Standards and Services segment · FY2019 · $4.02MFY2020Consumer Products segment · FY2020 · $47.09MIngredients segment · FY2020 · $9.20MAnalytical Reference Standards and Services segment · FY2020 · $2.97MFY2021Consumer Products segment · FY2021 · $56.71MIngredients segment · FY2021 · $7.41MAnalytical Reference Standards and Services segment · FY2021 · $3.34MFY2022Consumer Products segment · FY2022 · $60.11MIngredients segment · FY2022 · $8.74MAnalytical Reference Standards and Services segment · FY2022 · $3.20MFY2023Consumer Products segment · FY2023 · $69.53MIngredients segment · FY2023 · $11.14MAnalytical Reference Standards and Services segment · FY2023 · $2.91MFY2024Consumer Products segment · FY2024 · $76.77MIngredients segment · FY2024 · $19.81MAnalytical Reference Standards and Services segment · FY2024 · $3.01MFY2025Consumer Products segment · FY2025 · $97.67MIngredients segment · FY2025 · $28.68MAnalytical Reference Standards and Services segment · FY2025 · $3.08M
LineFY2025ShareChange
Consumer Products segment$97.67M75%+27.2%
Ingredients segment$28.68M22%+44.7%
Analytical Reference Standards and Services segment$3.08M2.4%+2.2%
Pharmaceuticals segment$0.00——
Corporate and Other Segment———
Total$129.42M

From the 10-K filed Mar 4, 2026NAGE

Medicinal chemicals & botanical products

Niagen Bioscience, Inc. is the 13th largest of the 41 covered companies the SEC files under this code, by revenue. SIC 2833

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR